A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Upadacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT - PsA 2
- Sponsors AbbVie
- 03 Dec 2018 Planned End Date changed from 1 Feb 2023 to 26 Feb 2022.
- 31 Aug 2018 Biomarkers information updated
- 29 Apr 2018 Planned End Date changed from 3 Jun 2022 to 1 Feb 2023.